Who is sponsoring NCT00202605?

NCT00202605 is sponsored by Shire.

What condition does NCT00202605 study?

NCT00202605 studies Attention Deficit Disorder With Hyperactivity.

Is NCT00202605 still recruiting?

NCT00202605 is currently completed. Last updated 24 June 2021.

Last reviewed 2021-06-24 · How we verify

NCT00202605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of SPD465 in Adults With ADHD

Completed Phase 2 Last updated 24 June 2021

What this trial tests

Phase 2 trial testing Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate in Attention Deficit Disorder With Hyperactivity in 72 participants. Completed in 6 January 2006.

Timeline

29 September 2005

Primary endpoint
6 January 2006

6 January 2006

Quick facts

Lead sponsor	Shire
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	72
Start date	29 September 2005
Primary completion	6 January 2006
Estimated completion	6 January 2006
Sites	4 locations across United States

Drugs / interventions tested

Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate

Conditions studied

Attention Deficit Disorder With Hyperactivity — all drugs for Attention Deficit Disorder With Hyperactivity →

Sponsor

Shire — full company profile →

Who can join

Adults 18 to 55, any sex, with Attention Deficit Disorder With Hyperactivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
Castells X, Blanco-Silvente L, Cunill R. · · 2018 · cited 66× · PMID 30091808 · DOI 10.1002/14651858.cd007813.pub3
Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.
Wigal T, Childress A, Frick G, Yan B, et al · · 2018 · cited 10× · PMID 29087231 · DOI 10.1080/00325481.2018.1389227

Verify or expand the search:

Other recruiting trials for Attention Deficit Disorder With Hyperactivity

Currently open trials in the same condition.

NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
NCT06764810 — Association Between Motor Skills and Sensory Profiles in Children With Typical and Atypical Development Aged 4 to 11 Yea · recruiting
NCT05621174 — The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD · NA · active not recruiting
NCT06369714 — Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. · NA · recruiting
NCT00001246 — Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers · active not recruiting

Other Shire trials

Trials by the same sponsor.

NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00202605 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 24 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00202605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing